The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1308 articles
Australia has released a groundbreaking clinical consensus statement on obesity and cardiovascular disease (CVD), marking a pivotal moment in medical practice. This new guidance places GLP-1 receptor agonists—a class of medications including semaglutide and tirzepatide—at the forefront of treatment strategies, offering clinicians a clear, practical pathway for improving patient outcomes.
While BMI is a primary factor, a range of underlying health conditions and personal histories can lead to a doctor declining a prescription for popular weight loss medications like Mounjaro and Wegovy. Understanding these criteria is vital before seeking treatment.
A peculiar new side effect, dubbed the 'Darth Vader' effect, is emerging with rapid weight loss achieved through GLP-1 medications. This article delves into the phenomenon, its potential causes, and the critical need for a balanced approach to weight management.
While generics have revolutionized drug affordability, newer biologics like those used for weight loss and diabetes face unique challenges. A new study reveals how varying international regulations are slowing the adoption of affordable biosimilars, impacting patient access and costs.
Millions are experiencing transformative weight loss with GLP-1 agonists like Ozempic and Wegovy. However, many encounter plateaus. Groundbreaking research from the NIH is shedding light on why this happens within the brain's appetite control centers, potentially paving the way for more effective and personalized treatment plans.
GLP-1 receptor agonists have revolutionized obesity and diabetes management, offering unprecedented appetite control. However, as adoption surges, especially in markets like India, medical experts emphasize that these powerful tools must be integrated with fundamental lifestyle changes and supportive public health infrastructure to ensure lasting success.
While GLP-1 medications are celebrated for their effectiveness in managing type 2 diabetes and aiding weight loss, a growing concern is the potential for nutrient deficiencies. This article delves into the science behind this 'under-the-radar' side effect and what proactive steps you can take.
A groundbreaking study reveals that the effectiveness of semaglutide, the active ingredient in popular weight loss medications like Ozempic and Wegovy, may be linked to the duration and intensity of chemical signals within specific brain cells. This research sheds light on why weight loss can plateau and offers clues for developing more sustained and effective future therapies.
New research is exploring the surprising potential of GLP-1 receptor agonists, known for their role in diabetes and weight management, to also influence mental well-being. This article delves into the latest findings and what they mean for patients.
